Marijuana Rescheduling Reaches Aug. 17 Deadline: What Cannabis Investors Should Watch Next

The federal marijuana rescheduling process reaches another milestone Monday, Aug. 17, as parties face a deadline to submit optional post-hearing briefs and proposed corrections to the record following the conclusion of a Drug Enforcement Administration hearing last month.

The deadline does not mean a decision on broader Schedule III treatment is coming Monday. Instead, it closes the latest stage of an administrative process that could ultimately determine whether marijuana beyond the state-licensed medical market moves from Schedule I to Schedule III under the Controlled Substances Act.

State-licensed medical marijuana has already received Schedule III treatment following action by the Justice Department in April.

The proceeding now underway addresses the broader rescheduling proposal, including marijuana sold through state-regulated adult-use markets.

What Happens After Aug. 17?

The DEA hearing concluded July 15 after 11 days of testimony.

Chief Administrative Law Judge Derek Julius gave the government and seven participating opponents of rescheduling until Aug. 17 to submit optional post-hearing briefs and proposed transcript corrections. The briefs can include closing arguments, proposed findings of fact and conclusions of law.

Julius will then review the hearing record and prepare a recommended decision on whether marijuana should be moved to Schedule III.

There is no announced deadline for that recommendation.

More importantly, Julius does not have the final word. His recommendation is advisory. DEA Administrator Terry Cole will ultimately decide whether the agency moves forward with broader rescheduling.

That makes Aug. 17 a procedural milestone rather than a binary decision date for investors.

Why Investors Are Watching 280E

The most immediate financial consequence of Schedule III for cannabis operators involves Section 280E of the federal tax code.

The provision prevents businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses from their federal taxes.

But the landscape changed substantially in April.

The Justice Department moved FDA-approved marijuana products and marijuana products regulated under qualifying state medical licenses to Schedule III while ordering the administrative proceeding to continue for the broader rescheduling proposal.

That means the industry is no longer waiting for an all-or-nothing rescheduling decision.

Qualifying state-licensed medical cannabis operations can now benefit from relief from Section 280E, while adult-use marijuana remains Schedule I. Foley Hoag attorneys identified the removal of 280E restrictions on deductions and credits for state-licensed medical cannabis operations as one of the immediate practical consequences of the April rescheduling order.

Broader Schedule III treatment could therefore expand that tax relief across a much larger portion of the U.S. cannabis industry.

For publicly traded operators, the potential impact ultimately comes down to cash flow: ordinary deductions for expenses could significantly change the effective tax burden of businesses currently subject to 280E.

The Hearing Does Not Guarantee Schedule III

The hearing examined questions including marijuana’s accepted medical use and public-health implications. But even a recommendation from Julius supporting Schedule III would not itself change marijuana’s federal status.

Cole would still need to issue the agency’s final decision, and broader rescheduling could face subsequent litigation.

Separate litigation is already challenging the administration’s April action placing state-licensed medical marijuana in Schedule III.

What Investors Should Watch Next

There are now three developments that matter.

First are the Aug. 17 briefs themselves. They could provide the clearest final arguments from the government and rescheduling opponents before Julius makes his recommendation.

Second is when Julius issues that recommendation. No timetable has been established, meaning Aug. 17 should not be treated as the beginning of a known countdown toward a final decision.

Third—and ultimately most important—is what DEA Administrator Cole does with it.

For cannabis companies and their investors, broader Schedule III treatment would not amount to federal legalization, because state-regulated adult-use cannabis would remain subject to significant federal restrictions.

But the tax implications alone make the proceeding financially significant, and medical cannabis has already crossed part of that threshold.